SEC Form 4 · accession 0001965808-26-000013
NEUROCRINE BIOSCIENCES INC · NBIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ingrid Delaet
Officer — Chief Regulatory Officer
Period of report
Jul 10, 2026
Accepted (ET)
Jul 13, 2026 · 4:27 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000914475
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 10, 2026 | M | 4,367 | $106.02 | A | 20,592 | D | |
| Common Stock | Jul 10, 2026 | S | 4,367 | $181.02 | D | 16,225 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock OptionF2 | $106.02 | Jul 10, 2026 | M | 4,367 | D | — | Feb 1, 2031 | Common Stock | 4,367 | 0 | D |
Explanation of responses
- F1The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
- F2Option granted February 1, 2021 and vested at 25% upon first anniversary (February 1, 2022) and remaining 75% vested in 36 equal monthly installments beginning on March 1, 2022.